© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Kazia Therapeutics Limited (KZIA) shows an Average True Range (ATR) of 1.9 and an Enterprise Value of 10.93M. Its average trading volume over the past 3 months is 611.73K, indicating liquidity. These fundamental metrics provide insight into KZIA's underlying financial health and market activity.
Kazia Therapeutics Limited (KZIA) technical indicators as of December 23, 2025: the SMA 20 is -12.93%, SMA 50 at 11.9%, and SMA 200 at 43.02%. The RSI 14 value is 48.52, suggesting its current momentum. These technical analysis signals help assess KZIA's price trends and potential future movements.
Kazia Therapeutics Limited (KZIA) stock performance overview as of December 23, 2025: The 52-week high is $80 (currently -42.53% below), and the 52-week low is $2.86 (currently 249.65% above). Over the past year, KZIA's performance is -87.99%, compared to the S&P 500's 10.56% change.
According to market data, Kazia Therapeutics Limited (KZIA) stock's recent performance metrics show that over the last month, KZIA is 29.2%, with a Year-to-Date (YTD) performance of -77.4%. Over the past year, the stock has seen a -87.99% change. These figures summarize KZIA's price movements across various periods, reflecting its historical returns.
According to current financial data, KZIA stock's P/E (TTM) ratio is -0.55, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for KZIA, including P/S (9.78), P/B (-3.36), and P/FCF (-3.27), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.